Inati A.; Taher A.; Ghorra S.; Koussa S.; Taha M.; Aoun E.; Sharara A.I.
(OXFORD9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND, 2005)
Thalassaemia patients with genotype 1 or 4 chronic hepatitis C virus (HCV) infection were randomised to receive peginterferon alpha-2a 180 mg-week ribavirin for 48 weeks. Primary efficacy variable was sustained viral ...